Ophiomics wins EIC accelerator funding in its pilot scheme. This hybrid funding scheme that includes a grant together with investment from the European Investment Bank, will permit Ophiomics to take HepatoPredcit to market and make a difference in selecting the right patients cancer for liver transplantation.
Related Posts
Ophiomics is present @EASL2024 in Milan. Visit us at Biotech Village BT3 to discover how HepatoPredict will
We are very happy to have been selected to participate in the Voice Leadership Program in the Training and Mentorship
Just back from three days of intense learning and networking with leaders in liver transplantation from all over the world.
Discussing the challenges of early and accurate diagnosis of displasia and how biomarkers can be the key to saving more
+351 211 369 829 